|
2023 Journal Article In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugateSonzini, Silvia, Caputo, Fanny, Mehn, Dora, Calzolai, Luigi, Even Borgos, Sven, Hyldbakk, Astrid, Treacher, Kevin, Li, Weimin, Jackman, Mark, Mahmoudi, Najet, Jayne Lawrence, M., Patterson, Claire, Owen, David, Ashford, Marianne and Akhtar, Nadim (2023). In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate. International Journal of Pharmaceutics, 637 122905, 1-14. doi: 10.1016/j.ijpharm.2023.122905 |
|
2022 Journal Article Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphomaFeeney, Orlagh M., Ardipradja, Katie, Noi, Ka Fung, Mehta, Dharmini, De Rose, Robert, Yuen, Daniel, Johnston, Angus P.R., Kingston, Lee, Ericsson, Cecilia, Elmore, Charles S., Hufton, Richard, Owen, David J., Ashford, Marianne B. and Porter, Christopher J.H. (2022). Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma. Journal of Controlled Release, 348, 420-430. doi: 10.1016/j.jconrel.2022.05.041 |
|
2021 Journal Article Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapyPatterson, Claire M., Balachander, Srividya B., Grant, Iain, Pop-Damkov, Petar, Kelly, Brian, McCoull, William, Parker, Jeremy, Giannis, Michael, Hill, Kathryn J., Gibbons, Francis D., Hennessy, Edward J., Kemmitt, Paul, Harmer, Alexander R., Gales, Sonya, Purbrick, Stuart, Redmond, Sean, Skinner, Matthew, Graham, Lorraine, Secrist, J. Paul, Schuller, Alwin G., Wen, Shenghua, Adam, Ammar, Reimer, Corinne, Cidado, Justin, Wild, Martin, Gangl, Eric, Fawell, Stephen E., Saeh, Jamal, Davies, Barry R. ... Ashford, Marianne B. (2021). Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Communications Biology, 4 (1) 112, 112. doi: 10.1038/s42003-020-01631-8 |
|
2020 Conference Publication Anti-cancer activity of a SN-38 nanoparticle, DEP® irinotecan, in human colon cancer xenograft modelsKelly, Brian D., McLeod, Victoria, Walker, Rachael, Schreuders, Jeannette, Jackson, Susan, Giannis, Michael, Dietinger, Christine, Xia, Shirley, Cargill, Anne, Seta, Aynaz, Hufton, Richard, Heery, Graham, Cullinane, Carleen and Owen, David J. (2020). Anti-cancer activity of a SN-38 nanoparticle, DEP® irinotecan, in human colon cancer xenograft models. AACR Annual Meeting 2020, Philadelphia, PA United States, 27-28 April 2020. Philadelphia, PA United States: American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.am2020-1715 |
|
2020 Conference Publication Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic indexAshford, Marianne B., Balachander, Srividya B., Graham, Lorraine, Grant, Iain, Gibbons, Francis D., Hill, Kathryn J., Harmer, Alexander R., Gales, Sonya, Redmond, Sean, Kelly, Brian, McCoull, William, Wen, Shenghua, Wild, Martin, Gangl, Eric, Owen, David J. and Davies, Barry R. (2020). Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index. AACR Annual Meeting 2020, Philadelphia, PA United States, 27-28 April 2020. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-1718 |
|
2020 Conference Publication Anticancer activity of the taxane nanoparticles, DEP® docetaxel and DEP® cabazitaxelKelly, Brian D., McLeod, Victoria, Walker, Rachael, Schreuders, Jeannette, Jackson, Susan, Giannis, Michael, Dietinger, Christine, Reitano, Pauline, Pathak, Rashmi, Xia, Shirley, Cargill, Anne, Seta, Aynaz, Hufton, Richard, Heery, Graham, Cullinane, Carleen and Owen, David J. (2020). Anticancer activity of the taxane nanoparticles, DEP® docetaxel and DEP® cabazitaxel. AACR Annual Meeting 2020, Philadelphia, PA United States, 27-28 April 2020. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-1716 |
|
2020 Other Outputs Dendrimer-drug conjugatesOwen, David James, Stanislsawski, Pauline, Giannis, Michael and Bernhard, Oliver (2020). Dendrimer-drug conjugates. |
|
2018 Journal Article Reducing dendrimer generation and PEG chain length increases drug release and promotes anti-cancer activity of PEGylated polylysine dendrimers conjugated with doxorubicin via a cathepsin-cleavable peptide linkerMehta, Dharmini, Leong, Nathania, McLeod, Victoria M., Kelly, Brian D., Pathak, Rashmi, Owen, David J., Porter, Christopher J.H. and Kaminskas, Lisa M. (2018). Reducing dendrimer generation and PEG chain length increases drug release and promotes anti-cancer activity of PEGylated polylysine dendrimers conjugated with doxorubicin via a cathepsin-cleavable peptide linker. Molecular Pharmaceutics, 15 (10) acs.molpharmaceut.8b00581, 4568-4576. doi: 10.1021/acs.molpharmaceut.8b00581 |
|
2018 Journal Article Doxorubicin conjugation and drug linker chemistry alter the intravenous and pulmonary pharmacokinetics of a PEGylated Generation 4 polylysine dendrimer in ratsLeong, Nathania J., Mehta, Dharmini, McLeod, Victoria M., Kelly, Brian D., Pathak, Rashmi, Owen, David J., Porter, Christopher J. H. and Kaminskas, Lisa M. (2018). Doxorubicin conjugation and drug linker chemistry alter the intravenous and pulmonary pharmacokinetics of a PEGylated Generation 4 polylysine dendrimer in rats. Journal of Pharmaceutical Sciences, 107 (9), 2509-2513. doi: 10.1016/j.xphs.2018.05.013 |
|
2017 Journal Article Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection siteRyan G.M., McLeod V.M., Mehta D., Kelly B.D., Stanislawski P.C., Owen D.J., Kaminskas L.M. and Porter C.J.H. (2017). Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site. Nanomedicine: Nanotechnology, Biology and Medicine, 13 (8), 2485-2494. doi: 10.1016/j.nano.2017.08.003 |
|
2017 Journal Article Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimersHaque, Shadabul, McLeod, Victoria M., Jones, Seth, Fung, Sandy, Whittaker, Michael, McIntosh, Michelle, Pouton, Colin, Owen, David J., Porter, Christopher J. H. and Kaminskas, Lisa M. (2017). Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. European Journal of Pharmaceutics and Biopharmaceutics, 119, 408-418. doi: 10.1016/j.ejpb.2017.07.005 |
|
2017 Other Outputs MacromoleculesOwen, David (2017). Macromolecules. |
|
2016 Journal Article A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated dendrimer following intravenous and aerosol administration to rats and sheepRyan, Gemma M., Bischof, Robert J., Enkhbaatar, Perenlei, McLeod, Victoria M., Chan, Linda J., Jones, Seth A., Owen, David J., Porter, Christopher J. H. and Kaminskas, Lisa M. (2016). A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated dendrimer following intravenous and aerosol administration to rats and sheep. Pharmaceutical Research, 33 (2), 510-525. doi: 10.1007/s11095-015-1806-z |
|
2015 Journal Article Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in ratsKaminskas, Lisa M., McLeod, Victoria M., Ascher, David B., Ryan, Gemma M., Jones, Seth, Haynes, John M., Trevaskis, Natalie L., Chan, Linda J., Sloan, Erica K., Finnin, Benjamin A., Williamson, Mark, Velkov, Tony, Williams, Elizabeth D., Kelly, Brian D., Owen, David J. and Porter, Christopher J. H. (2015). Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats. Molecular Pharmaceutics, 12 (2), 432-443. doi: 10.1021/mp500531e |
|
2014 Journal Article Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapyKaminskas, Lisa M., McLeod, Victoria M., Ryan, Gemma M., Kelly, Brian D., Haynes, John M., Williamson, Mark, Thienthong, Neeranat, Owen, David J. and Porter, Christopher J. H. (2014). Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. Journal of Controlled Release, 183 (1), 18-26. doi: 10.1016/j.jconrel.2014.03.012 |
|
2013 Journal Article PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicinRyan, Gemma M., Kaminskas, Lisa M., Bulitta, Juergen B., McIntosh, Michelle P., Owen, David J. and Porter, Christopher J. H. (2013). PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. Journal of Controlled Release, 172 (1), 128-136. doi: 10.1016/j.jconrel.2013.08.004 |
|
2013 Journal Article Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependentRyan, Gemma M., Kaminskas, Lisa M., Kelly, Brian D., Owen, David J., McIntosh, Michelle P. and Porter, Christopher J. H. (2013). Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Molecular Pharmaceutics, 10 (8), 2986-2995. doi: 10.1021/mp400091n |
|
2012 Journal Article Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor modelsKaminskas, Lisa M., McLeod, Victoria M., Kelly, Brian D., Cullinane, Carleen, Sberna, Gian, Williamson, Mark, Boyd, Ben J., Owen, David J. and Porter, Christopher J. H. (2012). Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Molecular Pharmaceutics, 9 (3), 422-432. doi: 10.1021/mp200522d |
|
2012 Journal Article A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systemsKaminskas, Lisa M., McLeod, Victoria M., Kelly, Brian D., Sberna, Gian, Boyd, Ben J., Williamson, Mark, Owen, David J. and Porter, Christopher J. H. (2012). A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine: Nanotechnology, Biology and Medicine, 8 (1), 103-111. doi: 10.1016/j.nano.2011.05.013 |
|
2011 Journal Article Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linkerKaminskas, Lisa M., Kelly, Brian D., McLeod, Victoria M., Sberna, Gian, Owen, David J., Boyd, Ben J. and Porter, Christopher J. H. (2011). Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. Journal of Controlled Release, 152 (2), 241-248. doi: 10.1016/j.jconrel.2011.02.005 |
